Therapeutic Area

Obstructive Sleep Apnea

Therapeutic area intelligence for Obstructive Sleep Apnea with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Lilly →

Assets

Dreem →

Phase →

Recent signals(3)

ClinicalJune 21, 2026

Study on Sleep Quality Improvement with CPAP in Obstructive Sleep Apnea

A study is underway to evaluate the impact of CPAP on sleep quality over multiple nights in a home setting.

ClinicalJune 15, 2026

Phase 3 Trial of Maridebart Cafraglutide in Obstructive Sleep Apnea Patients

A Phase 3 trial is underway to assess maridebart cafraglutide's efficacy and safety in OSA patients not using PAP therapy.

StrategyJune 15, 2026

Lilly's Zepbound® (tirzepatide) targets moderate obstructive sleep apnea in national campaign with Shaquille O'Neal

Lilly's Zepbound® is highlighted as the first prescription treatment for moderate-to-severe obstructive sleep apnea in adults with obesity.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Sleep Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.